Cargando…
PD-1 combined with lenvatinib and TACE for the transformational treatment of hepatocellular carcinoma combined with portal vein tumor thrombus: a case report and literature review
BACKGROUND: The prognosis of hepatocellular carcinoma combined with portal vein tumor thrombus is poor, with a median survival of only 3-6 months. PD-1 combined with targeted therapy may provide an opportunity for patients with BCLC C stage hepatocellular carcinoma combined with portal vein tumor th...
Autores principales: | Liu, Sheng, Xiong, Rui, Duan, Chuanyi, Tang, Jiang, Yin, Tao, Dai, Sisi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586726/ https://www.ncbi.nlm.nih.gov/pubmed/37869083 http://dx.doi.org/10.3389/fonc.2023.1199143 |
Ejemplares similares
-
TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021) -
A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023) -
Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
por: Zhao, Xiao-Hui, et al.
Publicado: (2022) -
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
por: Zou, Xinhua, et al.
Publicado: (2023) -
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
por: Qu, Shuping, et al.
Publicado: (2022)